Literature DB >> 17011826

New therapies for asthma.

Peter J Barnes1.   

Abstract

Asthma is an increasing global health problem, and many patients continue to suffer from chronic symptoms. However, current therapy with inhaled corticosteroids and a long-acting inhaled beta(2)-agonist is highly effective, safe and inexpensive. This poses a major hurdle to the development of new therapies that aim to improve on current treatments. An important unmet need is the treatment of severe asthma, which has different characteristics to mild and moderate asthma and is more similar to chronic obstructive pulmonary disease. Several new treatments are now under development but many of them are too specific, targeting a single receptor, enzyme or mediator, and are unlikely to have a major clinical impact. Another unmet need is the development of an effective oral therapy for mild and moderate asthma, but it is unlikely that such a treatment will be discovered because side effects might be a major problem. Prospects for a cure are currently remote but might arise from the development of vaccines that target the aberrant immune function in asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011826     DOI: 10.1016/j.molmed.2006.09.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  11 in total

Review 1.  Pharmacotherapy of critical asthma syndrome: current and emerging therapies.

Authors:  T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

2.  Allergen-induced airway inflammation and its therapeutic intervention.

Authors:  Paul M O'Byrne
Journal:  Allergy Asthma Immunol Res       Date:  2009-09-25       Impact factor: 5.764

Review 3.  Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions.

Authors:  M A Trevethick; S J Mantell; E F Stuart; A Barnard; K N Wright; M Yeadon
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

Review 4.  The acute management of asthma.

Authors:  Timothy E Albertson; Mark E Sutter; Andrew L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

Review 5.  The development of allergic inflammation.

Authors:  Stephen J Galli; Mindy Tsai; Adrian M Piliponsky
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

6.  Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.

Authors:  A S Naura; C P Hans; M Zerfaoui; D You; S A Cormier; M Oumouna; A H Boulares
Journal:  Clin Exp Allergy       Date:  2008-02-04       Impact factor: 5.018

7.  Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor κB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase.

Authors:  Amarjit S Naura; Hogyoung Kim; Jihang Ju; Paulo C Rodriguez; Joaquin Jordan; Andrew D Catling; Bashir M Rezk; Zakaria Y Abd Elmageed; Kusma Pyakurel; Abdelmetalab F Tarhuni; Mohammad Q Abughazleh; Youssef Errami; Mourad Zerfaoui; Augusto C Ochoa; A Hamid Boulares
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

8.  Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy.

Authors:  Sarah A Maher; Mark A Birrell; Maria G Belvisi
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

9.  Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma.

Authors:  Nicolas Mercado; Amir Hakim; Yoshiki Kobayashi; Sally Meah; Omar S Usmani; Kian Fan Chung; Peter J Barnes; Kazuhiro Ito
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  New drugs targeting Th2 lymphocytes in asthma.

Authors:  Gaetano Caramori; David Groneberg; Kazuhiro Ito; Paolo Casolari; Ian M Adcock; Alberto Papi
Journal:  J Occup Med Toxicol       Date:  2008-02-27       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.